These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 38307854)

  • 1. Risk of SARS-CoV-2 reinfection during multiple Omicron variant waves in the UK general population.
    Wei J; Stoesser N; Matthews PC; Khera T; Gethings O; Diamond I; Studley R; Taylor N; Peto TEA; Walker AS; Pouwels KB; Eyre DW;
    Nat Commun; 2024 Feb; 15(1):1008. PubMed ID: 38307854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.
    Lee CC; Chen CW; Yen HK; Lin YP; Lai CY; Wang JL; Groot OQ; Janssen SJ; Schwab JH; Hsu FM; Lin WH
    Clin Orthop Relat Res; 2024 Dec; 482(12):2193-2208. PubMed ID: 39051924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity.
    Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL
    J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining the optimum strategy for identifying adults and children with coeliac disease: systematic review and economic modelling.
    Elwenspoek MM; Thom H; Sheppard AL; Keeney E; O'Donnell R; Jackson J; Roadevin C; Dawson S; Lane D; Stubbs J; Everitt H; Watson JC; Hay AD; Gillett P; Robins G; Jones HE; Mallett S; Whiting PF
    Health Technol Assess; 2022 Oct; 26(44):1-310. PubMed ID: 36321689
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Collagenase injection versus limited fasciectomy surgery to treat Dupuytren's contracture in adult patients in the UK: DISC, a non-inferiority RCT and economic evaluation.
    Dias J; Tharmanathan P; Arundel C; Welch C; Wu Q; Leighton P; Armaou M; Corbacho B; Johnson N; James S; Cooke J; Bainbridge C; Craigen M; Warwick D; Brady S; Flett L; Jones J; Knowlson C; Watson M; Keding A; Hewitt C; Torgerson D
    Health Technol Assess; 2024 Dec; 28(78):1-262. PubMed ID: 39644138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study.
    Clark A; Jit M; Warren-Gash C; Guthrie B; Wang HHX; Mercer SW; Sanderson C; McKee M; Troeger C; Ong KL; Checchi F; Perel P; Joseph S; Gibbs HP; Banerjee A; Eggo RM;
    Lancet Glob Health; 2020 Aug; 8(8):e1003-e1017. PubMed ID: 32553130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.
    Liu Z; Alexander JL; Le K; Zhou X; Ibraheim H; Anandabaskaran S; Saifuddin A; Lin KW; McFarlane LR; Constable L; Seoane RC; Anand N; Bewshea C; Nice R; D'Mello A; Jones GR; Balarajah S; Fiorentino F; Sebastian S; Irving PM; Hicks LC; Williams HR; Kent AJ; Linger R; Parkes M; Kok K; Patel KV; Teare JP; Altmann DM; Boyton RJ; Hart AL; Lees CW; Goodhand JR; Kennedy NA; Pollock KM; Ahmad T; Powell N;
    EClinicalMedicine; 2023 Oct; 64():102249. PubMed ID: 37842172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded immune imprinting and neutralization spectrum by hybrid immunization following breakthrough infections with SARS-CoV-2 variants after three-dose vaccination.
    Jia T; Wang F; Chen Y; Liao G; Xu Q; Chen J; Wu J; Li N; Wang L; Yuan L; Wang D; Xie Q; Luo C; Luo H; Wang Y; Chen Y; Shu Y
    J Infect; 2024 Dec; 89(6):106362. PubMed ID: 39608577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
    Bryant A; Hiu S; Kunonga PT; Gajjar K; Craig D; Vale L; Winter-Roach BA; Elattar A; Naik R
    Cochrane Database Syst Rev; 2022 Sep; 9(9):CD015048. PubMed ID: 36161421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tobacco Product Use and Associated Factors Among Middle and High School Students - National Youth Tobacco Survey, United States, 2021.
    Gentzke AS; Wang TW; Cornelius M; Park-Lee E; Ren C; Sawdey MD; Cullen KA; Loretan C; Jamal A; Homa DM
    MMWR Surveill Summ; 2022 Mar; 71(5):1-29. PubMed ID: 35271557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Illness duration and symptom profile in symptomatic UK school-aged children tested for SARS-CoV-2.
    Molteni E; Sudre CH; Canas LS; Bhopal SS; Hughes RC; Antonelli M; Murray B; Kläser K; Kerfoot E; Chen L; Deng J; Hu C; Selvachandran S; Read K; Capdevila Pujol J; Hammers A; Spector TD; Ourselin S; Steves CJ; Modat M; Absoud M; Duncan EL
    Lancet Child Adolesc Health; 2021 Oct; 5(10):708-718. PubMed ID: 34358472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.
    Wolter N; Jassat W; Walaza S; Welch R; Moultrie H; Groome M; Amoako DG; Everatt J; Bhiman JN; Scheepers C; Tebeila N; Chiwandire N; du Plessis M; Govender N; Ismail A; Glass A; Mlisana K; Stevens W; Treurnicht FK; Makatini Z; Hsiao NY; Parboosing R; Wadula J; Hussey H; Davies MA; Boulle A; von Gottberg A; Cohen C
    Lancet; 2022 Jan; 399(10323):437-446. PubMed ID: 35065011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological treatments in panic disorder in adults: a network meta-analysis.
    Guaiana G; Meader N; Barbui C; Davies SJ; Furukawa TA; Imai H; Dias S; Caldwell DM; Koesters M; Tajika A; Bighelli I; Pompoli A; Cipriani A; Dawson S; Robertson L
    Cochrane Database Syst Rev; 2023 Nov; 11(11):CD012729. PubMed ID: 38014714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu F; Huang S; Liu X; Chen Q; Zhuang C; Zhao H; Han J; Jaen AM; Do TH; Peter JG; Dorado AG; Tirador LS; Zabat GMA; Villalobos REM; Gueco GP; Botha LLG; Iglesias Pertuz SP; Tan J; Zhu K; Quan J; Lin H; Huang Y; Jia J; Chu X; Chen J; Chen Y; Zhang T; Su Y; Li C; Ye X; Wu T; Zhang J; Xia N;
    Lancet Respir Med; 2023 Dec; 11(12):1075-1088. PubMed ID: 37979588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis.
    Filippini G; Del Giovane C; Vacchi L; D'Amico R; Di Pietrantonj C; Beecher D; Salanti G
    Cochrane Database Syst Rev; 2013 Jun; 2013(6):CD008933. PubMed ID: 23744561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
    Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
    Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.